Monovalent Anti-CD3 Fab Fragments Enhance Tumor Antigen Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as radio- and chemotherapy, are inefficient in targeting cancer cells specifically, causing damage to healthy tissues and often leading to recurrence, while immunotherapies face challenges in stimulating effective anti-tumor T cell responses due to poorly immunogenic tumor-associated antigens.
Innovation Solution
The use of monovalent anti-CD3 antibodies, specifically monovalent anti-CD3 Fab fragments, as adjuvants to enhance the immune response against tumor-associated antigens by increasing their immunogenicity without modifying their peptide sequences, thereby improving T cell activation and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (radio- and chemotherapy) are used to treat cancer, then cancer cells can be targeted and killed, but healthy tissues are damaged and side effects occur
Solution Approach 1:
The patent introduces monovalent anti-CD3 Fab fragments as an intermediary substance that mediates between the immune system and tumor cells. These Fab fragments bind to CD3 receptors on T cells, activating them to recognize and attack cancer cells specifically, while the Fc portion is modified to prevent activation of healthy tissues. This intermediary approach enables targeted cancer cell destruction without the collateral damage caused by conventional chemotherapy and radiotherapy.
2Reliability
If tumor-associated antigens are used to stimulate T cell response, then specific anti-tumor immunity can be generated, but the antigens are poorly immunogenic and fail to produce effective responses
Solution Approach 1:
The patent modifies the immunogenicity parameter of tumor-associated antigens by combining them with monovalent anti-CD3 Fab fragments. The Fab fragments change the physical and biological parameters of the antigen complex, enhancing its ability to stimulate T cell activation. This parameter change allows poorly immunogenic tumor-associated antigens to effectively trigger specific anti-tumor immune responses without altering the antigen sequences themselves.
3Productivity
If altered peptide ligands are used to increase immunogenicity, then T cell activation can be enhanced, but TCR specificity may be lost and off-target effects occur
Solution Approach 1:
The patent applies partial action by using monovalent anti-CD3 Fab fragments that provide only the co-stimulatory signal needed to enhance T cell activation, without completely replacing the natural antigen recognition process. The Fab fragments partially augment the immune response by binding to CD3 receptors and providing additional activation signals, while the T cells still require recognition of natural tumor-associated antigens via their TCRs. This partial action approach maintains TCR specificity for natural TAAs while enhancing activation efficiency, avoiding the off-target effects associated with altered peptide ligands.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monovalent anti-CD3 Fab fragments increase the immunogenicity of tumor-associated antigens, leading to enhanced T cell responses and reduced tumor burden in cancer models, specifically targeting cancer cells while sparing healthy tissues.
Implementation Method 1
monovalent anti-CD3 Fab fragments...bind to a CD3γδ dimer
Data Source
AI summary
This document provides methods and materials related to using monovalent anti-CD3 antibodies (e.g., monovalent anti-CD3 Fab fragments) as adjuvants to increase the immune response produced against an antigen (e.g., a tumor associated antigen). For example, vaccine compositions containing monovalent anti-CD3γε Fab fragments in combination with tumor associated antigens (e.g., tumor associated antigens having little or no immunogenicity in the absence of monovalent anti-CD3γε Fab fragments) alone or in combination with adjuvants for signals two and/or three required for full activation of T cell immune function, as well as methods and materials for using monovalent anti-CD3γε Fab fragments to increase the immune response produced against an antigen (e.g., a tumor associated antigen) within a mammal (e.g., a human) are provided.